title: GI perforation associated with bevacizumab.
authors.affiliation: Department of Medicine, Division of Gastroenterology & Hepatology, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors.forename: Sonia S
authors.initials: SS
authors.lastname: Yoon
authors.forename: Rene
authors.initials: R
authors.lastname: Rivera
authors.forename: Ashok
authors.initials: A
authors.lastname: Shah
authors.forename: Nuri
authors.initials: N
authors.lastname: Ozden
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D004378:Duodenal Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013525:Surgical Instruments / Q000009:adverse effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab